Any current/future new fundraising through debt or equity?

No explicit mention of any current or planned fundraising through debt or equity in the provided transcript. The company has a gross debt of INR 1,655 million and cash and cash equivalents of INR 1,760 million as of March 31, 2025, indicating a healthy liquidity position. Management highlighted disciplined capital expenditure plans (capex of INR 100-150 crores for FY '26) aligned with an asset-light model, suggesting controlled capital requirements. There is no direct reference to plans for raising fresh capital via debt or equity in the near future. Focus remains on optimizing operational eff

Any current/future capex/capital investment/strategic investment?

For FY '26, planned investments are in the range of INR 100 to 150 crores. Due to adoption of an asset-light model, actual cash outflow is expected to be significantly less than INR 100 crores. Investments will focus on implementing sizable tenders won at favorable rates. Capex mainly targets new radiology centers in Madhya Pradesh, Maharashtra, Delhi, and pathology collection centers in Assam and Orissa. Collection centers require minimal capex, primarily for basic infrastructure like refrigerators and basic test equipment. Strategic partnerships involve deferred equipment payments with 7% an

Future growth expectations in sales/revenue/volumes?

Growth momentum expected to resume in FY '26 with aspirations to surpass previous levels. Radiology and pathology volumes are increasing, with a balanced 50:50 revenue mix. Younger centers, especially in radiology, projected to mature and contribute significantly from FY '26 onwards. Retail business (B2C) anticipated to contribute 5-8% of revenue in FY '26, growing from ~3.5% in Q4 FY '25. Retail touch points are expanding rapidly (nearly 4x growth in 1 year), supporting growth. Overall revenue growth target is around 16%+ for FY '26, with expectations to outperform the industry. Expansion thr

Future growth expectations in earnings/operating earnings/profits/EPS?

FY25 revenue grew 16% YoY to INR 7,172 million; EBITDA rose 34% to INR 1,958 million with a 27% margin; net profit up 37% to INR 776 million with 11% margin. Management expects growth momentum to continue with aspirations to surpass FY25 levels into FY26 and beyond. Younger centers and new projects, including Maharashtra City MRI centers, are expected to mature and drive growth. ROCE and ROE have improved quarter-on-quarter, expected to improve further as business matures. Retail (B2C) segment is gaining traction; expected to contribute 5-8% of revenue in FY26 and improve margins gradually. FY

Current/ Expected Orderbook/ Pending Orders?

The company continues to win tenders and deepen its presence in Tier 2 and Tier 3 cities. There is a strong forward visibility supported by the order book and upcoming project pipeline. Specific details of tenders in the pipeline are not disclosed due to competition intensity. Various sizable tenders already won are expected to require investments of about INR 100-150 crores in FY '26. The management expresses confidence in surpassing current growth numbers with ongoing implementations. Overall, the outlook reflects a healthy order book with active pursuit of new government tenders and growing

IN US

Sale is live|00:00:00left today

Krsnaa Diagnostics LtdQ1 FY25Healthcare Services

Krsnaa Diagnostics Ltd Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹535P/E: 23.6Market Cap: ₹1.9K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→Growth momentum expected to resume in FY '26 with aspirations to surpass previous levels.
→Radiology and pathology volumes are increasing, with a balanced 50:50 revenue mix.
→Younger centers, especially in radiology, projected to mature and contribute significantly from FY '26 onwards.
→Retail business (B2C) anticipated to contribute 5-8% of revenue in FY '26, growing from ~3.5% in Q4 FY '25.
→Retail touch points are expanding rapidly (nearly 4x growth in 1 year), supporting growth.
→Overall revenue growth target is around 16%+ for FY '26, with expectations to outperform the industry.
→Expansion through PPP tenders and selective asset-light models will sustain growth.
→Improvement in infrastructure and operational efficiencies expected to enhance margins alongside growth.

Margin guidance

Category 3

→FY25 revenue grew 16% YoY to INR 7,172 million; EBITDA rose 34% to INR 1,958 million with a 27% margin; net profit up 37% to INR 776 million with 11% margin.
→Management expects growth momentum to continue with aspirations to surpass FY25 levels into FY26 and beyond.
→Younger centers and new projects, including Maharashtra City MRI centers, are expected to mature and drive growth.
→ROCE and ROE have improved quarter-on-quarter, expected to improve further as business matures.
→Retail (B2C) segment is gaining traction; expected to contribute 5-8% of revenue in FY26 and improve margins gradually.
→FY26 capex planned around INR 100-150 crores, with practical cash outflows significantly lower due to asset-light models.
→Margins are expected to stabilize or improve further with operational efficiencies and changing business mix.
→Overall, management targets mid-to-high teens growth with improving margins and profitability in coming years.

3 more insights locked — sign up free to unlock

Fundraise plans

→No explicit mention of any current or planned fundraising through debt or equity in the provided transcript.
→The company has a gross debt of INR 1,655 million and cash and cash equivalents of INR 1,760 million as of March 31, 2025, indicating a healthy liquidity position.
→Management highlighted disciplined capital expenditure plans (capex of INR 100-150 crores for FY '26) aligned with an asset-light model, suggesting controlled capital requirements.
→There is no direct reference to plans for raising fresh capital via debt or equity in the near future.
→Focus remains on optimizing operational efficiencies, receivables management, and leveraging existing infrastructure to drive growth.
→Any material update on fundraising would likely be communicated separately but is not disclosed in this earnings call.

Order book

Yes

→The company continues to win tenders and deepen its presence in Tier 2 and Tier 3 cities.
→There is a strong forward visibility supported by the order book and upcoming project pipeline.
→Specific details of tenders in the pipeline are not disclosed due to competition intensity.
→Various sizable tenders already won are expected to require investments of about INR 100-150 crores in FY '26.
→The management expresses confidence in surpassing current growth numbers with ongoing implementations.
→Overall, the outlook reflects a healthy order book with active pursuit of new government tenders and growing retail business channels.

Capex plans

Yes

→For FY '26, planned investments are in the range of INR 100 to 150 crores.
→Due to adoption of an asset-light model, actual cash outflow is expected to be significantly less than INR 100 crores.
→Investments will focus on implementing sizable tenders won at favorable rates.
→Capex mainly targets new radiology centers in Madhya Pradesh, Maharashtra, Delhi, and pathology collection centers in Assam and Orissa.
→Collection centers require minimal capex, primarily for basic infrastructure like refrigerators and basic test equipment.
→Strategic partnerships involve deferred equipment payments with 7% annual interest to support infrastructure.
→Investments align with expanding PPP business and retail network, including a 4x increase in retail touch points across 4 states.
→Capex has reduced from INR 193 crores in FY '24 to INR 111 crores in FY '25 due to operational efficiencies and asset-light strategies.

How does Krsnaa Diagnostics Ltd rank vs peers in Healthcare Services?

Pro feature

1Krsnaa Diagnostics Ltd

Rev 3Mar 3

See full Healthcare Services sector rankings

Want more stocks like Krsnaa Diagnostics Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio